FunPep Company Limited (4881) AI Stock Analysis

• Market Cap: ¥4.54B
• Dividend Yield: N/A
• Average Volume (3M): 245.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.19
• Revenue Growth: -16.23%
• EPS Growth: -51.84%
• Country: JP
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -17.06
• Shares Outstanding: 40,563,800
• 10 Day Avg. Volume: 262,310
• 30 Day Avg. Volume: 245,823
• PEG Ratio: -0.03
• Price to Book (P/B): 2.13
• Price to Sales (P/S): 9943.96
• P/FCF Ratio: -2.25
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -34.5
• Revenue Forecast (FY): ¥500.00M

• Rating: 50 Neutral
• Price Target: ¥112.00 ▲(41.77% Upside)
• Action: Reiterated Date: 03/06/26
• Date: Action: Reiterated 03/06/26

The score is held down primarily by weak financial performance (persistent losses, negative cash flow, and shrinking equity/assets), which outweighs the debt-free balance sheet. Technicals provide a meaningful offset as the stock is in an uptrend with positive momentum. Valuation remains constrained because the company is loss-making (negative P/E) and no dividend yield is available.

Positive Factors

Debt-free balance sheet

Zero reported debt materially reduces near-term solvency risk and interest obligations. For a small biotech, lack of leverage preserves strategic optionality to pursue trials, partnerships, or licensing without servicing debt, giving management time to execute over the next several months.

Narrowing losses in some years

Intermittent narrowing of operating and net losses suggests management has taken cost-control or prioritization actions. If sustained, this trajectory can extend runway, improve operational discipline, and make the company a more viable partner or financing candidate over a 2–6 month horizon.

Lean operating structure

A 15-person headcount implies a very lean cost base and operational flexibility. Structurally low fixed overhead can stretch available cash, enable focused R&D spending, and reduce near-term financing needs compared with larger peers, supporting survivability while seeking partnerships.

Negative Factors

Persistent negative cash flow

Consistent annual negative operating and free cash flow, culminating in ~-¥1.39B in 2025, is a structural cash-burn problem. Over 2–6 months this necessitates external funding or asset monetization; failure to secure capital would constrain R&D and operational continuity.

Severe revenue contraction

A ~95% revenue collapse from an already small base indicates weak commercial traction or a disrupted revenue stream. Structurally volatile and tiny revenue undermines scalability and makes achieving break-even materially harder without new products, partnerships, or durable revenue drivers.

Eroding financial cushion

Declining equity and assets over multiple years reflect cumulative losses and shrinking financial resources. Even with no debt, a diminished balance sheet reduces ability to absorb setbacks, fund trials, or negotiate favorable collaborations, heightening funding and execution risk.

FunPep Company Limited Business Overview & Revenue Model

Company Description

FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, a functional peptide for skin ulcer; FPP003, an antibody-inducing peptide that is in Phase II clinical study for the treatment of psoriasis in Australia, as well as phase II clinical trial for ankylosing spondylitis in Japan; and FPP004X, an antibody-inducing peptide for pollinosis. It is also developing FPP006, a corona peptide vaccine; and FPP005, a antibody including peptide for psoriasis. FunPep Company Limited was incorporated in 2013 and is based in Tokyo, Japan.

How the Company Makes Money

FunPep Company Limited generates revenue primarily through the development and commercialization of its peptide-based drugs. The company earns income by licensing its proprietary technologies and products to pharmaceutical companies and healthcare organizations. Additionally, FunPep may benefit from research and development collaborations, where it partners with other entities to co-develop treatments and shares in the resultant profits. The company's earnings are also bolstered by potential government grants or funding for research initiatives, as well as milestone payments and royalties from successfully commercialized drugs.

FunPep Company Limited Financial Statement Overview

Summary

Financial quality is weak due to very small and highly volatile revenue (sharp contraction in 2025), persistently large operating/net losses, and consistently negative operating cash flow/free cash flow with deterioration in 2025. The main positive is a debt-free balance sheet, but equity and total assets have declined over time, indicating an eroding financial cushion.

Income Statement

Revenue is small and highly volatile, with a sharp contraction in 2025 (down ~95% year over year) after an already low base. Profitability is consistently weak: gross profit is negative across all years, and operating losses and net losses remain very large (2025 net loss ~¥1.9B). While losses narrowed in some years versus prior peaks, the company has not demonstrated a sustained path toward break-even.

Balance Sheet

The balance sheet is conservatively levered with zero debt reported across periods, which reduces solvency risk. However, equity has declined meaningfully from 2020 to 2025, reflecting ongoing losses and cash burn. Total assets have also trended down over time, indicating a shrinking financial cushion despite the lack of leverage.

Cash Flow

Cash generation is structurally weak: operating cash flow and free cash flow are negative every year, with a notable deterioration in 2025 (operating cash flow about -¥1.39B). Although free cash flow improved in 2024 versus 2023, the overall pattern is persistent cash burn that likely requires continued funding support over time.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.03M	314.00K	6.13M	530.00K	1.07M	126.87M
Gross Profit	-38.13M	-41.58M	-37.86M	-680.29M	-12.84M	-535.63M
EBITDA	-1.36B	-1.61B	-859.23M	-952.00M	-1.16B	-745.04M
Net Income	-1.40B	-1.91B	-889.09M	-933.42M	-1.17B	-682.26M
Balance Sheet
Total Assets	3.01B	1.98B	3.11B	2.49B	2.99B	3.36B
Cash, Cash Equivalents and Short-Term Investments	2.33B	1.77B	2.35B	1.79B	2.25B	3.01B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	538.78M	516.73M	563.18M	189.32M	298.11M	188.67M
Stockholders Equity	2.47B	1.46B	2.55B	2.30B	2.69B	3.18B
Cash Flow
Free Cash Flow	0.00	-1.39B	-537.60M	-989.87M	-1.07B	-892.79M
Operating Cash Flow	0.00	-1.39B	-536.74M	-988.82M	-1.05B	-887.47M
Investing Cash Flow	0.00	-993.00K	-30.83M	-1.05M	-19.14M	-4.75M
Financing Cash Flow	0.00	810.93M	1.12B	537.81M	245.13M	282.68M

FunPep Company Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 79.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4881, the sentiment is Positive. The current price of 79 is below the 20-day moving average (MA) of 95.65, below the 50-day MA of 89.44, and below the 200-day MA of 100.20, indicating a bullish trend. The MACD of 3.05 indicates Negative momentum. The RSI at 64.02 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4881.

FunPep Company Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4570	72 Outperform	¥14.02B	41.40	―	―	12.91%	37.96%
177A	67 Neutral	¥6.23B	24.52	―	1.62%	―	―
4571	52 Neutral	¥13.49B	-12.44	-26.70%	―	172.39%	8.27%
2183	52 Neutral	¥7.16B	-2.65	―	5.44%	-15.42%	-879.08%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4881	50 Neutral	¥4.54B	-1.63	―	―	-16.23%	-51.84%
4587	46 Neutral	¥192.27B	-57.13	-10.16%	―	-62.47%	-134.06%